Bruker 향후 성장
Future 기준 점검 3/6
Bruker (는) 각각 연간 103% 및 4.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 103.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.4% 로 예상됩니다.
핵심 정보
103.0%
이익 성장률
103.09%
EPS 성장률
| Life Sciences 이익 성장 | 17.5% |
| 매출 성장률 | 4.6% |
| 향후 자기자본이익률 | 14.43% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 09 May 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Apr 29
BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path
Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.내러티브 업데이트 • Apr 15
BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings
Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.
내러티브 업데이트 • Apr 01
BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E
Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.Seeking Alpha • Mar 31
Bruker: A Better, Yet Speculative Proposition
Summary Bruker's shares have declined 40% since January, pressured by weak 2025 results and a cautious 2026 outlook. 2025 saw organic sales decline 4%, high leverage (~3x), and significant M&A activity, raising concerns about capital allocation. 2026 guidance calls for modest 4–5% sales growth, 1–2% organic, and adjusted EPS of $2.10–$2.15, lowering valuation to 15–16x earnings. While conviction remains low due to uneven execution, the risk-reward is improving, warranting consideration of a small speculative position on further dips. Read the full article on Seeking Alpha내러티브 업데이트 • Mar 18
BRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E
Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.내러티브 업데이트 • Mar 03
BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E
Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.내러티브 업데이트 • Feb 17
BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions
Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.분석 기사 • Feb 15
Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report
It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...내러티브 업데이트 • Feb 03
BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple
Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.내러티브 업데이트 • Jan 20
BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple
Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.내러티브 업데이트 • Jan 06
BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations
Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.내러티브 업데이트 • Dec 17
BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations
Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.내러티브 업데이트 • Dec 03
BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations
Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.분석 기사 • Nov 26
Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry
Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...내러티브 업데이트 • Nov 19
BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook
Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.내러티브 업데이트 • Nov 03
BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience
Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.분석 기사 • Aug 10
Why Investors Shouldn't Be Surprised By Bruker Corporation's (NASDAQ:BRKR) 31% Share Price Plunge
NasdaqGS:BRKR 1 Year Share Price vs Fair Value Explore Bruker's Fair Values from the Community and select yours The...내러티브 업데이트 • Aug 06
Renewed Biopharma Funding And Cost Savings Will Revitalize Markets
Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).분석 기사 • Jun 25
Revenues Working Against Bruker Corporation's (NASDAQ:BRKR) Share Price
Bruker Corporation's ( NASDAQ:BRKR ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now...분석 기사 • May 31
A Look At The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Key Insights The projected fair value for Bruker is US$43.42 based on 2 Stage Free Cash Flow to Equity Bruker's...분석 기사 • May 16
Bruker's (NASDAQ:BRKR) Soft Earnings Don't Show The Whole Picture
The market for Bruker Corporation's ( NASDAQ:BRKR ) shares didn't move much after it posted weak earnings recently. We...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 3,950 | N/A | 306 | 409 | 7 |
| 12/31/2027 | 3,744 | 161 | 274 | 350 | 12 |
| 12/31/2026 | 3,588 | 120 | 272 | 353 | 12 |
| 3/31/2026 | 3,459 | -36 | 22 | 140 | N/A |
| 12/31/2025 | 3,437 | -22 | 14 | 134 | N/A |
| 9/30/2025 | 3,439 | -24 | -11 | 94 | N/A |
| 6/30/2025 | 3,443 | 80 | 49 | 166 | N/A |
| 3/31/2025 | 3,446 | 80 | 175 | 295 | N/A |
| 12/31/2024 | 3,366 | 113 | 136 | 251 | N/A |
| 9/30/2024 | 3,241 | 305 | 157 | 267 | N/A |
| 6/30/2024 | 3,120 | 352 | 168 | 273 | N/A |
| 3/31/2024 | 3,001 | 402 | 181 | 284 | N/A |
| 12/31/2023 | 2,965 | 427 | 243 | 350 | N/A |
| 9/30/2023 | 2,818 | 319 | 206 | 316 | N/A |
| 6/30/2023 | 2,715 | 319 | 201 | 342 | N/A |
| 3/31/2023 | 2,621 | 312 | 149 | 284 | N/A |
| 12/31/2022 | 2,531 | 297 | 145 | 274 | N/A |
| 9/30/2022 | 2,506 | 275 | 119 | 242 | N/A |
| 6/30/2022 | 2,476 | 274 | 114 | 196 | N/A |
| 3/31/2022 | 2,458 | 282 | 176 | 262 | N/A |
| 12/31/2021 | 2,418 | 277 | 190 | 282 | N/A |
| 9/30/2021 | 2,362 | 270 | 254 | 347 | N/A |
| 6/30/2021 | 2,264 | 238 | 312 | 405 | N/A |
| 3/31/2021 | 2,118 | 204 | 304 | 395 | N/A |
| 12/31/2020 | 1,988 | 158 | 235 | 332 | N/A |
| 9/30/2020 | 1,960 | 158 | 169 | 265 | N/A |
| 6/30/2020 | 1,970 | 165 | 140 | 235 | N/A |
| 3/31/2020 | 2,035 | 177 | 141 | 234 | N/A |
| 12/31/2019 | 2,073 | 197 | N/A | 213 | N/A |
| 9/30/2019 | 2,026 | 207 | N/A | 210 | N/A |
| 6/30/2019 | 1,972 | 189 | N/A | 185 | N/A |
| 3/31/2019 | 1,925 | 184 | N/A | 210 | N/A |
| 12/31/2018 | 1,896 | 180 | N/A | 240 | N/A |
| 9/30/2018 | 1,873 | 98 | N/A | 211 | N/A |
| 6/30/2018 | 1,842 | 92 | N/A | 219 | N/A |
| 3/31/2018 | 1,813 | 84 | N/A | 166 | N/A |
| 12/31/2017 | 1,766 | 79 | N/A | 154 | N/A |
| 9/30/2017 | 1,706 | 151 | N/A | 142 | N/A |
| 6/30/2017 | 1,664 | 161 | N/A | 142 | N/A |
| 3/31/2017 | 1,621 | 152 | N/A | 177 | N/A |
| 12/31/2016 | 1,611 | 154 | N/A | 131 | N/A |
| 9/30/2016 | 1,619 | 146 | N/A | 190 | N/A |
| 6/30/2016 | 1,621 | 111 | N/A | 208 | N/A |
| 3/31/2016 | 1,646 | 119 | N/A | 188 | N/A |
| 12/31/2015 | 1,624 | 102 | N/A | 229 | N/A |
| 9/30/2015 | 1,654 | 66 | N/A | 149 | N/A |
| 6/30/2015 | 1,677 | 60 | N/A | 108 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: BRKR 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.
수익 vs 시장: BRKR (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.
고성장 수익: BRKR 향후 3년 내에 수익을 낼 것으로 예상됩니다.
수익 대 시장: BRKR 의 수익(연간 4.6%)이 US 시장(연간 11.6%)보다 느리게 성장할 것으로 예상됩니다.
고성장 매출: BRKR 의 수익(연간 4.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: BRKR의 자본 수익률은 3년 후 14.4%로 낮을 것으로 예상됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/11 22:49 |
| 종가 | 2026/05/11 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Bruker Corporation는 29명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |